Jennifer Beachell is Vice President, Disease Area Commercial Leader, Autoantibody, within the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, Jen is responsible for developing and executing the commercial strategy to support the discovery, development, and launch of new therapeutics within the Autoantibody disease area.
Jen also provides leadership to global commercial teams to establish effective partnerships with cross-functional and regional stakeholders to ensure launch readiness for new products, and to maximize current in-market assets worldwide.
Before joining Janssen in 2020 as part of the Johnson & Johnson acquisition of Momenta Pharmaceuticals, Jen served as the Vice President of Commercial, leading commercial strategy and execution at Momenta to develop novel medicines for rare disease patients. In this role, Jen also led the integration of Momenta into the Johnson & Johnson Global Commercial Strategy Organization.
Prior to Momenta, Jen served as President of the U.S. commercial business at Novelion Therapeutics where she was responsible for relaunching the commercial portfolio of rare ultra-orphan disease products. Jen’s team led and was responsible for market access, marketing, sales, business analytics, market research, training, and partnering on business development initiatives.
Jen brings more than 20 years of commercial experience to Janssen with prior roles including WellDoc, Human Genome Sciences, Medimmune, and Ortho Biotech. She has a background in health care consulting with organizations such as The Lewin Group and Mercer.
She holds an undergraduate degree from Smith College and an MBA from The Wharton School of Business at the University of Pennsylvania.
Follow Jen on LinkedIn here.